JP2011501740A - 抗細菌組成物 - Google Patents
抗細菌組成物 Download PDFInfo
- Publication number
- JP2011501740A JP2011501740A JP2010527533A JP2010527533A JP2011501740A JP 2011501740 A JP2011501740 A JP 2011501740A JP 2010527533 A JP2010527533 A JP 2010527533A JP 2010527533 A JP2010527533 A JP 2010527533A JP 2011501740 A JP2011501740 A JP 2011501740A
- Authority
- JP
- Japan
- Prior art keywords
- phage
- bacteria
- composition according
- composition
- lysis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 10
- 241000894006 Bacteria Species 0.000 claims abstract description 76
- 230000009089 cytolysis Effects 0.000 claims abstract description 60
- 238000000034 method Methods 0.000 claims description 18
- 230000002147 killing effect Effects 0.000 claims description 11
- 208000035143 Bacterial infection Diseases 0.000 claims description 9
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 9
- 210000003928 nasal cavity Anatomy 0.000 claims description 9
- 244000052769 pathogen Species 0.000 claims description 8
- 230000001717 pathogenic effect Effects 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 241000191967 Staphylococcus aureus Species 0.000 claims description 6
- 241000607142 Salmonella Species 0.000 claims description 4
- 244000052616 bacterial pathogen Species 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 239000004166 Lanolin Substances 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 229940039717 lanolin Drugs 0.000 claims description 3
- 235000019388 lanolin Nutrition 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000012188 paraffin wax Substances 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 241001453380 Burkholderia Species 0.000 claims description 2
- 241000589876 Campylobacter Species 0.000 claims description 2
- 241000194033 Enterococcus Species 0.000 claims description 2
- 241000588722 Escherichia Species 0.000 claims description 2
- 241000589989 Helicobacter Species 0.000 claims description 2
- 241000588748 Klebsiella Species 0.000 claims description 2
- 241000589248 Legionella Species 0.000 claims description 2
- 208000007764 Legionnaires' Disease Diseases 0.000 claims description 2
- 241000186781 Listeria Species 0.000 claims description 2
- 241000186359 Mycobacterium Species 0.000 claims description 2
- 241000589516 Pseudomonas Species 0.000 claims description 2
- 241000607768 Shigella Species 0.000 claims description 2
- 241000191940 Staphylococcus Species 0.000 claims description 2
- 241000194017 Streptococcus Species 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 241000193403 Clostridium Species 0.000 claims 2
- 241001112696 Clostridia Species 0.000 claims 1
- 241000588650 Neisseria meningitidis Species 0.000 claims 1
- 241001515965 unidentified phage Species 0.000 abstract description 42
- 230000001580 bacterial effect Effects 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 23
- 230000002101 lytic effect Effects 0.000 description 22
- 208000015181 infectious disease Diseases 0.000 description 18
- 206010052428 Wound Diseases 0.000 description 16
- 208000027418 Wounds and injury Diseases 0.000 description 16
- 238000009472 formulation Methods 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
- 239000004472 Lysine Substances 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 210000002421 cell wall Anatomy 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229960003085 meticillin Drugs 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 241000193163 Clostridioides difficile Species 0.000 description 2
- 101700012268 Holin Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 description 2
- 206010041925 Staphylococcal infections Diseases 0.000 description 2
- 241000239110 Staphylococcus virus K Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000004777 protein coat Anatomy 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 102100036263 Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Human genes 0.000 description 1
- 101001001786 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000123769 Listeria virus A511 Species 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010061372 Streptococcal infection Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- -1 anionic phosphate polyol Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000008316 intracellular mechanism Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000001320 lysogenic effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 238000001066 phage therapy Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/40—Viruses, e.g. bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/36—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10111—Myoviridae
- C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10211—Podoviridae
- C12N2795/10232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Agronomy & Crop Science (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0719438A GB0719438D0 (en) | 2007-10-04 | 2007-10-04 | Anti-bacteria compositions |
| GB0800790A GB0800790D0 (en) | 2008-01-16 | 2008-01-16 | Anti-bacteria compositions |
| PCT/GB2008/003363 WO2009044163A2 (en) | 2007-10-04 | 2008-10-03 | Anti-bacteria compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014165105A Division JP6053727B2 (ja) | 2007-10-04 | 2014-08-14 | 抗細菌組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011501740A true JP2011501740A (ja) | 2011-01-13 |
| JP2011501740A5 JP2011501740A5 (https=) | 2011-11-17 |
Family
ID=40526766
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010527533A Pending JP2011501740A (ja) | 2007-10-04 | 2008-10-03 | 抗細菌組成物 |
| JP2014165105A Active JP6053727B2 (ja) | 2007-10-04 | 2014-08-14 | 抗細菌組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014165105A Active JP6053727B2 (ja) | 2007-10-04 | 2014-08-14 | 抗細菌組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20110182863A1 (https=) |
| EP (1) | EP2197284B1 (https=) |
| JP (2) | JP2011501740A (https=) |
| CN (1) | CN101835384B (https=) |
| AU (1) | AU2008306626B2 (https=) |
| CA (1) | CA2700646C (https=) |
| ES (1) | ES2632367T3 (https=) |
| WO (1) | WO2009044163A2 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014533943A (ja) * | 2011-11-07 | 2014-12-18 | ノヴォリティックス リミテッドＮｏｖｏｌｙｔｉｃｓ Ｌｉｍｉｔｅｄ | 新規なバクテリオファージ |
| WO2024190909A1 (ja) | 2023-03-15 | 2024-09-19 | 国立感染症研究所長が代表する日本国 | 組換えファージ及びその調製方法 |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010212280B2 (en) * | 2009-08-12 | 2015-09-24 | Buddhist Tzu Chi Medical Foundation | Phage of acinetobacter Baumannii |
| CN103458694A (zh) * | 2011-04-01 | 2013-12-18 | 通用电气公司 | 用于治理微生物诱导的腐蚀和环境损害及用于改进废水处理工艺的方法和组合物 |
| DE102013106455A1 (de) | 2013-06-20 | 2014-12-24 | Airbus Defence and Space GmbH | Verfahren zur Dekontamination von bakteriologischen Verunreinigungen |
| US10517908B2 (en) | 2015-08-13 | 2019-12-31 | Armata Pharmaceuticals, Inc. | Therapeutic bacteriophage compositions |
| EP3436041B1 (en) | 2016-03-31 | 2023-05-24 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
| AU2017240064B8 (en) | 2016-03-31 | 2021-11-11 | Gojo Industries, Inc. | Antimicrobial peptide stimulating sanitizing composition |
| WO2017173240A1 (en) | 2016-03-31 | 2017-10-05 | Gojo Industries, Inc. | Antimicrobial peptide stimulating cleansing composition |
| JP2020500860A (ja) | 2016-11-23 | 2020-01-16 | ゴジョ・インダストリーズ・インコーポレイテッド | プロバイオティック／プレバイオティックな有効成分を含む消毒薬組成物 |
| CN110719784A (zh) | 2017-02-13 | 2020-01-21 | 阿玛塔制药公司 | 治疗性噬菌体组合物 |
| CN112218659A (zh) * | 2018-01-02 | 2021-01-12 | 阿玛塔制药股份有限公司 | 用于治疗葡萄球菌感染的治疗性噬菌体组合物 |
| WO2019136108A1 (en) | 2018-01-02 | 2019-07-11 | Ampliphi Biosciences Corporation | Bacteriophage compositions for treating pseudomonas infections |
| FR3110599B1 (fr) * | 2020-05-19 | 2024-07-26 | Vetophage | Nouvelles souches de bacteriophages et leurs utilisations |
| EP3972620A1 (fr) * | 2019-05-21 | 2022-03-30 | Vetophage | Nouvelles souches de bactériophages et leurs utilisations |
| EP4720263A1 (en) * | 2023-06-01 | 2026-04-08 | University of Florida Research Foundation, Incorporated | Phage therapy utilizing a unique cocktail of pseudomonas aeruginosa phages |
| CN118165942B (zh) * | 2024-03-22 | 2024-12-13 | 青岛润达生物科技有限公司 | 一株沙门氏菌噬菌体rdp-sa-22022及其连续化生产工艺和应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003080823A2 (en) * | 2002-03-25 | 2003-10-02 | University Of Warwick | Bacteriophages useful for therapy and prophylaxis of bacterial infections |
| US20040146490A1 (en) * | 2000-04-20 | 2004-07-29 | Mount Sinai Hospital | Antibacterial therapy for multi-drug resistant bacteria |
| WO2006074460A2 (en) * | 2005-01-10 | 2006-07-13 | Omnilytics, Incorporated | Method of treating food products |
| JP2007504869A (ja) * | 2003-09-10 | 2007-03-08 | フライシュマン，ウィルヘルム | 傷表面に作用物質を適用するための装置及び方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4957686A (en) * | 1990-02-06 | 1990-09-18 | Norris Alan H | Use of bacteriophages to inhibit dental caries |
| US5811093A (en) * | 1994-04-05 | 1998-09-22 | Exponential Biotherapies, Inc. | Bacteriophage genotypically modified to delay inactivations by the host defense system |
| WO1995027043A1 (en) * | 1994-04-05 | 1995-10-12 | Exponential Biotherapies, Inc. | Antibacterial therapy with genotypically modified bacteriophage |
| US6335012B1 (en) * | 1997-10-31 | 2002-01-01 | Vincent Fischetti | Use of bacterial phage associated lysing enzymes for treating bacterial infections of the mouth and teeth |
| ATE313341T1 (de) * | 2000-01-11 | 2006-01-15 | Intralytix Inc | Polymermischungen als bioabbaubare matrizen zur herstellung von biokompositen |
| NZ538098A (en) * | 2002-07-08 | 2007-01-26 | Ebi Food Safety B V | Lytic phage P100 ATCC deposit designation PTA-4383 to control listeria monocytogenes in foodstuffs and in food processing plants and treat animals infected |
| KR100781669B1 (ko) * | 2006-06-20 | 2007-12-03 | 주식회사 인트론바이오테크놀로지 | 황색포도상구균 특이적 사멸능을 갖는 박테리오파지 |
-
2008
- 2008-10-03 CN CN200880110119.7A patent/CN101835384B/zh not_active Expired - Fee Related
- 2008-10-03 US US12/733,940 patent/US20110182863A1/en not_active Abandoned
- 2008-10-03 JP JP2010527533A patent/JP2011501740A/ja active Pending
- 2008-10-03 ES ES08806507.3T patent/ES2632367T3/es active Active
- 2008-10-03 EP EP08806507.3A patent/EP2197284B1/en active Active
- 2008-10-03 WO PCT/GB2008/003363 patent/WO2009044163A2/en not_active Ceased
- 2008-10-03 AU AU2008306626A patent/AU2008306626B2/en active Active
- 2008-10-03 CA CA2700646A patent/CA2700646C/en active Active
-
2014
- 2014-08-14 JP JP2014165105A patent/JP6053727B2/ja active Active
-
2015
- 2015-04-14 US US14/686,315 patent/US20150216179A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040146490A1 (en) * | 2000-04-20 | 2004-07-29 | Mount Sinai Hospital | Antibacterial therapy for multi-drug resistant bacteria |
| WO2003080823A2 (en) * | 2002-03-25 | 2003-10-02 | University Of Warwick | Bacteriophages useful for therapy and prophylaxis of bacterial infections |
| JP2007504869A (ja) * | 2003-09-10 | 2007-03-08 | フライシュマン，ウィルヘルム | 傷表面に作用物質を適用するための装置及び方法 |
| WO2006074460A2 (en) * | 2005-01-10 | 2006-07-13 | Omnilytics, Incorporated | Method of treating food products |
Non-Patent Citations (4)
| Title |
|---|
| JPN6013026460; Ａｐｐｌ． Ｅｎｖｉｒｏｎ． Ｍｉｃｒｏｂｉｏｌ．， ２００５， Ｖｏｌ．７１， Ｎｏ．４， ｐｐ．１８３６-１８４２ * |
| JPN6013026462; Ａｎｔｉｍｉｃｒｏｂ． Ａｇｅｎｔｓ Ｃｈｅｍｏｔｈｅｒ．， ２００５， Ｖｏｌ．４９， Ｎｏ．７， ｐｐ．２９３４-２９４０ * |
| JPN6013026465; Ｊ． Ｆｅｒｍｅｎｔａｔｉｏｎ ａｎｄ Ｂｉｏｅｎｇｉｎｅｅｒｉｎｇ， １９９７， Ｖｏｌ．８３， Ｎｏ．６， ｐｐ．５１１-５１６ * |
| JPN6014015473; Ｌｅｔｔ． Ａｐｐｌ． Ｍｉｃｒｏｂｉｏｌ．， ２００７．０９， Ｖｏｌ．４５， ｐｐ．３１３-３１７ * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014533943A (ja) * | 2011-11-07 | 2014-12-18 | ノヴォリティックス リミテッドＮｏｖｏｌｙｔｉｃｓ Ｌｉｍｉｔｅｄ | 新規なバクテリオファージ |
| US9623058B2 (en) | 2011-11-07 | 2017-04-18 | Ampliphi Biosciences Corporation | Bacteriophages |
| JP2018068297A (ja) * | 2011-11-07 | 2018-05-10 | ノヴォリティックス リミテッドＮｏｖｏｌｙｔｉｃｓ Ｌｉｍｉｔｅｄ | 新規なバクテリオファージ |
| WO2024190909A1 (ja) | 2023-03-15 | 2024-09-19 | 国立感染症研究所長が代表する日本国 | 組換えファージ及びその調製方法 |
| EP4682252A1 (en) | 2023-03-15 | 2026-01-21 | Japan Institute for Health Security | Recombinant phage and method for preparing same |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009044163A2 (en) | 2009-04-09 |
| JP6053727B2 (ja) | 2016-12-27 |
| WO2009044163A3 (en) | 2010-02-11 |
| CN101835384A (zh) | 2010-09-15 |
| US20110182863A1 (en) | 2011-07-28 |
| AU2008306626B2 (en) | 2013-05-09 |
| EP2197284B1 (en) | 2017-04-12 |
| US20150216179A1 (en) | 2015-08-06 |
| CN101835384B (zh) | 2014-07-16 |
| ES2632367T3 (es) | 2017-09-12 |
| EP2197284A2 (en) | 2010-06-23 |
| JP2015007087A (ja) | 2015-01-15 |
| CA2700646A1 (en) | 2009-04-09 |
| CA2700646C (en) | 2019-10-29 |
| AU2008306626A1 (en) | 2009-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6053727B2 (ja) | 抗細菌組成物 | |
| Kakasis et al. | Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review | |
| Matsuzaki et al. | Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage ϕMR11 | |
| Wang et al. | Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa | |
| Vieira et al. | Phage therapy to control multidrug-resistant Pseudomonas aeruginosa skin infections: in vitro and ex vivo experiments | |
| Sisakhtpour et al. | The characteristic and potential therapeutic effect of isolated multidrug-resistant Acinetobacter baumannii lytic phage | |
| AU2010212280B2 (en) | Phage of acinetobacter Baumannii | |
| US20020001590A1 (en) | Antibacterial therapy for multi-drug resistant bacteria | |
| EP1677834B1 (en) | Defined dose therapeutic phage | |
| Capparelli et al. | Selection of an Escherichia coli O157: H7 bacteriophage for persistence in the circulatory system of mice infected experimentally | |
| WO2009087356A1 (en) | Host range change phage | |
| Erol et al. | The effect of phage-antibiotic combination strategy on multidrug-resistant Acinetobacter baumannii biofilms | |
| Ali et al. | Therapeutic potential of a newly isolated bacteriophage against multi-drug resistant Enterococcus faecalis infections: in vitro and in vivo characterization | |
| Majdani et al. | Isolation and characterization of lytic bacteriophages against Pseudomonas aeruginosa isolates from human infections in the north-west of Iran | |
| Ali et al. | Phage-antibiotic synergism against Salmonella typhi isolated from stool samples of typhoid patients | |
| Horiuk et al. | Characteristics of bacteriophages of the Staphylococcus aureus variant bovis | |
| Kulsuwan et al. | Lytic capability of bacteriophages (Family Myoviridae) on Burkholderia pseudomallei | |
| Ali et al. | Extraction, purification and therapeutic use of bacteriophage endolysin against multi-drug resistant Staphylococcus aureus: In vivo and in vitro study. | |
| US20040146490A1 (en) | Antibacterial therapy for multi-drug resistant bacteria | |
| CA2504331A1 (en) | Bacteriophage having modified holin and uses thereof | |
| AU2015264918A1 (en) | Anti-bacteria compositions | |
| Leta et al. | Assessment of therapeutic potential of bacteriophages to control Escherichia coli infection in Swiss mice model | |
| Agbo et al. | Isolation and analysis of the biological characteristics of a novel bacteriophage vB_SauP_P992 against Staphylococcus aureus | |
| Teklemariam et al. | Isolation and characterization of a novel lytic phage, VB_PseuP-SA22, and its efficacy against carbapenem-resistant Pseudomonas aeruginosa. Antibiotics 2023; 12: 497 | |
| Atique et al. | Brief overview on bacteriophage therapy; alternative to antibiotics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110928 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110928 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130531 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130809 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130816 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130927 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131004 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131031 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140414 |